skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All


Show More


Show More

Show More


Show More

Show More

99+ Total results for product and free and sample content found


A Positive Outlook For Deals, With Election Year Caveats

By Jessica Merrill 17 Feb 2020


Industry advisers at the BIO CEO & Investor meeting remained optimistic about the pharmaceutical deal environment in 2020 – even with the uncertainty around a looming US election year.

Topic BioPharmaceutical


Another Alzheimer's Setback As Roche And Lilly Drugs Fail

By Kevin Grogan 17 Feb 2020


As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.

Topic Alzheimer's Disease

Generics Bulletin

Sun Finds US ‘Challenging’

By Penelope MacRae 17 Feb 2020


Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

Topic Deal trends

Medtech Insight

Coronavirus All FDA Inspections Of Chinese Manufacturing Facilities Come To Screeching Halt

By Shawn M. Schmitt 17 Feb 2020


In a late Friday news statement, agency head Stephen Hahn also warned of possible “shortages of critical medical products” The US agency has suspended all routine surveillance inspections in China through the end of March because of coronavirus fears, commissioner Stephen Hahn announced late on 14 February. Despite expecting medical product shortages, Hahn said the agency is being proactive: “We are not waiting for drug and device manufacturers to report shortages to us” before acting. The timing of Hahn’s statement – at 6 p.m. EST on a Friday, at the beginning of a three-day US holiday weekend – suggests he isn’t particularly excited to share the information.

Topic Coronavirus

In Vivo

Regular Acceptance Of Simulation Studies More Likely In 2020s

By William Masters 17 Feb 2020


Lyon, France-based Novadiscovery is developing a user-facing technology to run in silico studies, a method it expects to cut development costs and improve trial success rates. But acceptance of “new” data types is often a concern for drug developers, despite world-leading regulatory bodies stating their desire for 21st century approaches.

Topic BioPharmaceutical

Pink Sheet

FDA Broke Catalyst's Orphan Exclusivity Due To Pricing, Not Clinical, Concerns, Firm Claims

By Brenda Sandburg 17 Feb 2020

FDA Emails

Suit against agency reveals internal discussions to approve Jacobus' Ruzurgi despite Catalyst's orphan exclusivity for the same drug; Sen. Bernie Sanders urged FDA to address price of Catalyst's Firdapse (amifampridine).


The Changing Landscape of Pharma Marketing

13 Feb 2020

The Changing Landscape of Pharma Marketing

Understanding the intricacies of pharma marketing can be tough, but Skipta has you covered. A leading social network of specialized online medical communities for over 700,000 verified healthcare professionals, Skipta can pinpoint and connect you to your exact targets – quickly and easily.


Pharma Marketing 2020: Maximising product launch success amid complex legislative change

13 Feb 2020

Pharma Marketing 2020: Maximising product launch success amid complex legislative change

Healthcare professionals are notoriously hard to reach with new product messaging. Skipta makes it easier. A social network for verified physicians, Skipta communities are segmented by area of expertise or disease state. Use Skipta to create custom, targeted campaigns to reach your audience when they’re most ready to engage. 


38th Annual J.P. Morgan Healthcare Conference Review

07 Feb 2020

38th Annual J.P. Morgan Healthcare Conference Review

Go inside the 2020 J.P. Morgan Healthcare Conference with exclusive reporting from Scrip. Explore the most important news from each day, and access exclusive, real-time interviews with pharma and biotech movers and shakers, and discover insights into the trends revealed at this year’s event. 

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: